Pharma Deals 2024. Guarded optimism seems to be the mood of the biopharmaceutical industry to start 2024. Pharma and life sciences deal volumes grew by 2%, but values increased by 22% due to the number of announced megadeals—transactions with a value in excess of us$5bn—increasing.
[adobe stock] in the first few weeks of 2024, oncology remained a central focus area for m&a deals. The iqvia pharma deals review of 2023 provides an insightful overview of deal activity in 2023, as well as an outlook for 2024.
Oelrich Aims To Do Deals In The €1 Billion To €5 Billion Range;
The global life sciences industry.
The Role Of The Regulators And Their Impact.
Pharma and life sciences deal volumes grew by 2%, but values increased by 22% due to the number of announced megadeals—transactions with a value in excess of us$5bn—increasing.
Request A Free Trial Now.
Images References :
In 2024, We Expect Similar.
The global life sciences industry.
Last Year Brought A Stock Market Slide And Layoffs For More Than 150 Drug.
Last year, the value of the top 10 m&a deals in the biopharma industry came to $115.8 billion, outranking prior sums from 2022, 2021 and 2020, which came to $65 billion, $53.
